Literature DB >> 22821892

Runx2 isoform I controls a panel of proinvasive genes driving aggressiveness of papillary thyroid carcinomas.

Valentina Sancisi1, Gloria Borettini, Sally Maramotti, Moira Ragazzi, Ione Tamagnini, Davide Nicoli, Simonetta Piana, Alessia Ciarrocchi.   

Abstract

CONTEXT: The ability of tumor cells to invade adjacent tissues is governed by a complicated network of molecular signals, most of which have not yet been identified. In a recent work, we reported that the transcriptional regulator Id1 contributes to thyroid cancer progression by powering the invasion capacity of tumor cells.
OBJECTIVE: The intent of this work was to further investigate the biology of invasive thyroid tumors, through the analysis of the molecular interactions existing between Id1 and some of its target genes and through the characterization of the function of these factors in the progression of thyroid tumors.
RESULTS: We showed that Id1 controls the expression of the Runx2 isoform I and that this transcription factor plays a central role in mediating the Id1 proinvasive function in thyroid tumor cells. We demonstrated that Runx2 regulates proliferation, migration, and invasiveness by activating a panel of genes involved in matrix degradation and cellular invasion, which we previously identified as Id1 target genes in thyroid tumor cells. Finally, we show that Runx2 is strongly expressed in metastatic human thyroid tumors both at the primary site and in metastases.
CONCLUSION: Overall, our experiments demonstrate the existence of a previously unknown molecular axis that controls thyroid tumor invasiveness by altering the ability of tumor cells to interact with the surrounding microenvironment. These factors could prove to be valuable markers that permit early diagnosis of aggressive thyroid tumors.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22821892      PMCID: PMC3462932          DOI: 10.1210/jc.2012-1903

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  41 in total

1.  Frequent attenuation of the WWOX tumor suppressor in osteosarcoma is associated with increased tumorigenicity and aberrant RUNX2 expression.

Authors:  Kyle C Kurek; Sara Del Mare; Zaidoun Salah; Suhaib Abdeen; Hussain Sadiq; Suk-Hee Lee; Eugenio Gaudio; Nicola Zanesi; Kevin B Jones; Barry DeYoung; Gail Amir; Mark Gebhardt; Matthew Warman; Gary S Stein; Janet L Stein; Jane B Lian; Rami I Aqeilan
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

2.  Tissue specific regulation of VEGF expression during bone development requires Cbfa1/Runx2.

Authors:  E Zelzer; D J Glotzer; C Hartmann; D Thomas; N Fukai; S Soker; B R Olsen
Journal:  Mech Dev       Date:  2001-08       Impact factor: 1.882

3.  Runx2 deficiency in mice causes decreased thyroglobulin expression and hypothyroidism.

Authors:  Toyoshi Endo; Tetsuro Kobayashi
Journal:  Mol Endocrinol       Date:  2010-04-07

4.  Genomic promoter occupancy of runt-related transcription factor RUNX2 in Osteosarcoma cells identifies genes involved in cell adhesion and motility.

Authors:  Margaretha van der Deen; Jacqueline Akech; David Lapointe; Sneha Gupta; Daniel W Young; Martin A Montecino; Mario Galindo; Jane B Lian; Janet L Stein; Gary S Stein; Andre J van Wijnen
Journal:  J Biol Chem       Date:  2011-12-09       Impact factor: 5.157

5.  The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion.

Authors:  Jitesh Pratap; Amjad Javed; Lucia R Languino; Andre J van Wijnen; Janet L Stein; Gary S Stein; Jane B Lian
Journal:  Mol Cell Biol       Date:  2005-10       Impact factor: 4.272

6.  Inhibitor of DNA binding-1 induces mesenchymal features and promotes invasiveness in thyroid tumour cells.

Authors:  Alessia Ciarrocchi; Simonetta Piana; Roberto Valcavi; Giorgio Gardini; Bruno Casali
Journal:  Eur J Cancer       Date:  2010-12-09       Impact factor: 9.162

7.  Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion.

Authors:  Vasily Vasko; Allan V Espinosa; William Scouten; Huiling He; Herbert Auer; Sandya Liyanarachchi; Alexander Larin; Victoria Savchenko; Gary L Francis; Albert de la Chapelle; Motoyasu Saji; Matthew D Ringel
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-12       Impact factor: 11.205

8.  Ectopic runx2 expression in mammary epithelial cells disrupts formation of normal acini structure: implications for breast cancer progression.

Authors:  Jitesh Pratap; Karen M Imbalzano; Jean M Underwood; Nathalie Cohet; Karthiga Gokul; Jacqueline Akech; Andre J van Wijnen; Janet L Stein; Anthony N Imbalzano; Jeffrey A Nickerson; Jane B Lian; Gary S Stein
Journal:  Cancer Res       Date:  2009-08-18       Impact factor: 12.701

9.  Tollip is a mediator of protein sumoylation.

Authors:  Alessia Ciarrocchi; Romina D'Angelo; Chiara Cordiglieri; Ada Rispoli; Spartaco Santi; Massimo Riccio; Simona Carone; Anna Laura Mancia; Simone Paci; Elena Cipollini; Davide Ambrosetti; Marialuisa Melli
Journal:  PLoS One       Date:  2009-02-09       Impact factor: 3.240

10.  Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions.

Authors:  J Akech; J J Wixted; K Bedard; M van der Deen; S Hussain; T A Guise; A J van Wijnen; J L Stein; L R Languino; D C Altieri; J Pratap; E Keller; G S Stein; J B Lian
Journal:  Oncogene       Date:  2009-11-16       Impact factor: 9.867

View more
  22 in total

Review 1.  Runx2, an inducer of osteoblast and chondrocyte differentiation.

Authors:  Toshihisa Komori
Journal:  Histochem Cell Biol       Date:  2018-01-22       Impact factor: 4.304

2.  Thyroid Hormone Receptor-β (TRβ) Mediates Runt-Related Transcription Factor 2 (Runx2) Expression in Thyroid Cancer Cells: A Novel Signaling Pathway in Thyroid Cancer.

Authors:  Frances E Carr; Phillip W L Tai; Michael S Barnum; Noelle E Gillis; Katherine G Evans; Thomas H Taber; Jeffrey H White; Jennifer A Tomczak; Diane M Jaworski; Sayyed K Zaidi; Jane B Lian; Janet L Stein; Gary S Stein
Journal:  Endocrinology       Date:  2016-06-02       Impact factor: 4.736

3.  Cadherin-6 promotes EMT and cancer metastasis by restraining autophagy.

Authors:  M Gugnoni; V Sancisi; G Gandolfi; G Manzotti; M Ragazzi; D Giordano; I Tamagnini; M Tigano; A Frasoldati; S Piana; A Ciarrocchi
Journal:  Oncogene       Date:  2016-07-04       Impact factor: 9.867

4.  The Thyroid Hormone Receptor-RUNX2 Axis: A Novel Tumor Suppressive Pathway in Breast Cancer.

Authors:  Eric L Bolf; Noelle E Gillis; Michael S Barnum; Caitlin M Beaudet; Grace Y Yu; Jennifer A Tomczak; Janet L Stein; Jane B Lian; Gary S Stein; Frances E Carr
Journal:  Horm Cancer       Date:  2019-12-21       Impact factor: 3.869

Review 5.  RUNX2 and the PI3K/AKT axis reciprocal activation as a driving force for tumor progression.

Authors:  Karine A Cohen-Solal; Rajeev K Boregowda; Ahmed Lasfar
Journal:  Mol Cancer       Date:  2015-07-25       Impact factor: 27.401

6.  The significance of Runx2 mediating alcohol-induced Brf1 expression and RNA Pol III gene transcription.

Authors:  Zaifa Hong; Zeng Fang; Junxia Lei; Ganggang Shi; Yanmei Zhang; Zhiming He; Wen Li B; Shuping Zhong
Journal:  Chem Biol Interact       Date:  2020-03-18       Impact factor: 5.192

7.  Thyroid Hormone Receptor β Suppression of RUNX2 Is Mediated by Brahma-Related Gene 1-Dependent Chromatin Remodeling.

Authors:  Noelle E Gillis; Thomas H Taber; Eric L Bolf; Caitlin M Beaudet; Jennifer A Tomczak; Jeffrey H White; Janet L Stein; Gary S Stein; Jane B Lian; Seth Frietze; Frances E Carr
Journal:  Endocrinology       Date:  2018-06-01       Impact factor: 4.736

8.  Cadherin 6 is a new RUNX2 target in TGF-β signalling pathway.

Authors:  Valentina Sancisi; Greta Gandolfi; Moira Ragazzi; Davide Nicoli; Ione Tamagnini; Simonetta Piana; Alessia Ciarrocchi
Journal:  PLoS One       Date:  2013-09-12       Impact factor: 3.240

9.  Aberrant expression of posterior HOX genes in well differentiated histotypes of thyroid cancers.

Authors:  Monica Cantile; Giosuè Scognamiglio; Lucia La Sala; Elvira La Mantia; Veronica Scaramuzza; Elena Valentino; Fabiana Tatangelo; Simona Losito; Luciano Pezzullo; Maria Grazia Chiofalo; Franco Fulciniti; Renato Franco; Gerardo Botti
Journal:  Int J Mol Sci       Date:  2013-11-01       Impact factor: 5.923

10.  RUNX2 expression in thyroid and breast cancer requires the cooperation of three non-redundant enhancers under the control of BRD4 and c-JUN.

Authors:  Valentina Sancisi; Gloria Manzotti; Mila Gugnoni; Teresa Rossi; Greta Gandolfi; Giulia Gobbi; Federica Torricelli; Francesca Catellani; Italo Faria do Valle; Daniel Remondini; Gastone Castellani; Moira Ragazzi; Simonetta Piana; Alessia Ciarrocchi
Journal:  Nucleic Acids Res       Date:  2017-11-02       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.